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ABSTRACT 
Background    
This truly stentless porcine valve is composite, without Dacron and implanted supra-annularly.  Ten year 
analysis with magnetic resonance imaging is presented. 
Methods 
From 1992 to 2002, 402 patients (mean 73.5 yrs) had aortic valve replacement.  Associated procedures 
were required in 252 patients (63%).  Serial echoes provided 1340 studies.  Clinical follow-up was 100%.  
Magnetic Resonance Imaging focused on aortic annulus extensibility.  
Results 
The 30 day mortality was 0.99% (4 deaths).  Morbidity comprised (a) thromboembolism (40 patients 
including 18 patients with permanent strokes); (b) endocarditis (nine patients); (c) re-operation (nine 
patients) - peri-prosthetic leak (2), endocarditis (5), technical needle damage (1) and structural 
degeneration (1).  Of 402 valves over 10 years, five valves were explanted, one only  for structural failure.  
Except for endocarditis (2), no late deaths (69 pts, 1.5 months – 5.7 yrs) were valve related.  
Echocardiography demonstrated low gradients with good orifice areas, excellent ventricular regression (p 
= 0.0001 pre and post-operative comparisons) and late incompetence - mild (45 pts) and moderate (nine 
pts).  No living patient has severe incompetence.  Magnetic Resonance Imaging demonstrated the annulus  
‘expanding and relaxing’ throughout the cardiac cycle, the mean increase in cross-sectional area being 
37%, resembling normal aortic root dynamics.  
Conclusion 
Elderly patients received this hemodynamically acceptable valve with its simple, supra-annular 
implantation and satisfactory mid-term morbid-free lifestyle to 10 years maximum follow-up.  With only 
one structural failure, restoration of valve annular extensibility may have a favourable influence on long-
term durability.   
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Introduction 
The first clinically implanted porcine aortic valve xenografts in 1965-69 were stentless [1-4], but the 
introduction of both a stent and glutaraldehyde preservation by Carpentier saw their rapid disappearance 
[5].  Their revival by David [6] in 1987 initiated the appearance of many designs with varying degrees of 
dacron cloth support of either the whole porcine valve or partial dacron support over the right coronary 
leaflet base, where, in the intact porcine animal, ventricular muscle gave support to this leaflet.  
In 1991 the authors returned to the use of a composite trileaflet porcine valve constructed from 
three size-matched non-coronary leaflets [7] (CryoLife Inc. Atlanta, Georgia).  Originally in 1967-69 this 
same composite design, but formaldehyde preserved, had been used by us at The Prince Charles Hospital 
in 129 patients.  From this experience [8], the concept of a composite valve, single suture line technique 
and supra-annular implantation was established and proven to be reliable.  However, the preservation 
solution proved inadequate.  In the early 1970s the re-operation rate was 50% at 5 years.  This poor valve 
durability was unacceptable.  With the subsequent well documented performance of glutaraldehyde 
preservation of porcine valves, the reintroduction of the composite valve appeared justified in the early 
1990s [9]. 
Previous reports have detailed the clinical performance of this stentless valve [7, 10-12] and the 
implementation techniques [13-16], which are very different to those of other stentless valves.  These 
details are not repeated except to briefly summarize several very important features.  The very small 5-6 
mm cuff of xenograft aortic wall distal to the valve hinge and the absence of a proximal cuff of this 
composite valve enable a simple, rapid single suture line implantation technique [14].  Because of this 
small aortic cuff no problems have been encountered with low-lying host coronary ostia.  Additional 
advantages of the supra-annular placement have included good exposure for the small aortic root, 
provision of an effective central flow and non-obstructive orifice with low transvalvar gradients 
mimicking those of the homograft valve.  The chosen valve size, being one size larger i.e. a 25mm valve 
into a 23mm host annulus, allows for discrepancies of annular and sinotubular diameters. 
The difference between supra-annular implantation and annular placement, very pertinent to the 
understanding of the hemodynamic performance and of the magnetic resonance imaging (MRI) findings 
of restoration of annular extensibility, are demonstrated in Fig. 1.  The residual native annulus becomes 
subvalvar. 
The purpose of this report is firstly to update previous clinical appraisals of this valve now that 
maximum follow-up is over 10 years.  Secondly, it is to emphasize the ease of technical implantation with 
the low early mortality and mid-term morbidity in an elderly patient population, and thirdly, to focus on a 
novel postulation from MRI studies that the observed restoration of the extensibility of the aortic valve 
annulus following supra-annular implantation of a truly stentless device may favorably enhance long-term 
durability. 
 
Patients and Methods 
From 30th December 1992 to 4th December 2002, 402 patients received the CryoLife-O’Brien model 300 
stentless porcine aortic xenograft for aortic valve replacement (AVR).  All patients were either contacted 
by telephone, seen personally by a physician/cardiologist/surgeon and their records perused during 2002 
through to the first half of 2003.  The follow-up was 100% complete and although it has now entered its 
12th year, this report focuses on the first 10 year analysis.  All patient events up-to and including the year 
of 2002 have been included in this analysis.  The evaluation of patient progress and the definitions and 
assessment of morbid events have been conducted strictly in accordance with the ‘Guidelines for 
Reporting Morbidity and Mortality after Cardiac Valvular Operations’ [17-18].  The mean patient age was 
73.5 years  (range 55 – 89 yrs), males 58%, 73 patients (18.2%) being 80 years or older at the time of 
operation.  Concomitant procedures were required in 252 patients (63%), most of whom (186=46%) were 
coronary artery bypass operations (CABG: 2.4 grafts/patient). Forty-two patients (10.4%) had left 
ventricular (LV) myomectomy.  While initially in this series, intraoperative transoesophageal echo 
examination was employed, later transthoracic echo performed at the pre-hospital or preoperative phase 
became sufficient. Subsequent echoes postoperatively at the 4-5th day, at 6 months, 1 year and 1-2 yearly 
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thereafter were performed.  Late serial echocardiography included some 1340 studies over the ten years in 
order to gain knowledge of the late valve function.    
Magnetic Resonance Imaging:  As an ongoing study, ten patients who some years previously had 
received this stentless valve (range 2-11 yrs: mean 6 yrs), were imaged to assess the change in the area of 
the aortic valve annulus throughout the cardiac cycle.  MRI was performed on a 1.5 Tesla Signa 
Twinspeed system (GE Medical Systems, Milwaukee, WI) with a 4-element cardiac phased array coil.  
Steady state free precession imaging was used to identify the aortic valve annulus which was seen as an 
area of low signal intensity beneath the valve [Fig. 2].  ECG gated cine phase contrast images with full  
R-R coverage were then obtained directly through the annulus, orthogonal to the left ventricular outflow 
tract [Fig 3]. Image acquisition using a segmented k-space technique, occurred over approximately 16 
cardiac cycles (depending on heart rate) to produce a single cine loop representing one cardiac cycle.  
Some through plane motion was apparent due to the fixed imaging plane relative to cardiac motion but 
due to the tubular nature of the annulus, this was thought not to introduce significant variation. 
Image analysis was performed on an Advantage Windows workstation using Medis flow analysis 
software. The mean cross sectional areas and flow volumes were calculated and plotted (Figs 4a and 4b) 
at 30 intervals throughout the cardiac cycle. 
Operative Procedures remained essentially standardized throughout the 10 years.  These include 
full median sternotomy, aortic cannulation, intermittent anti-and retrograde crystalloid cardioplegia, CO2 
insufflation into the pericardial cavity during cardiopulmonary bypass, LV decompression via right 
superior pulmonary vein cannulation and distal CABG graft anastimoses prior to transverse aortotomy.  
Valve excision was followed by aggressive calcific debridement of the native valve annulus remnant.  As 
this area remains exposed to the blood stream with supra-valvar implantation, as much as possible, care 
was taken to leave this annulus area reasonably ‘smooth’ without obvious semi-loose fragments or 
spicules of calcium.  Measurement of both annular and sinotubular diameter (STD) dictated the selection 
of valve size (Table 1).  With supra-valvar implantation, using a single layer continuous 3/0 
polypropylene suture, a valve of at least one size larger than the annulus is selected i.e. a 23mm porcine 
valve for a 21mm host annulus.  If the STD was 29mm and the valve annulus only 25mm, a valve of 
29mm would be implanted supra-annularly (i.e. 2 sizes larger than the annulus diameter).  Therefore in 
assessing the level and importance of any gradient, appropriate analysis of echocardiographic transvalvar 
gradients demands recording of the host annulus diameter in addition to the larger porcine valve diameter.  
Table 1 outlines the sizes of the implanted porcine valve and host annulus. 
Left ventricular myomectomy was carried out in 42 patients.  The indication was made at 
operation rather than on any preoperative echo study.  After native value excision, if the L.V. myocardium 
was prominent and the free edge of the anterior mitral valve leaflet was not readily visible through the 
aortic orifice, then longitudinal/vertical LV myomectomy was performed. 
Institutional approval for the clinical use of this valve was obtained from The Prince Charles 
Hospital (14 October 1992) and St Andrews Ethics Committee (1994).  The Therapeutic Goods 
Administration of Australia (TGA) was notified according to the Clinical Trial Notification (CTN) 
category (17 November 1992).  All patients gave informed consent to their receiving this stentless valve.   
Statistical analysis:  Outcomes were reported according to the guidelines for reporting valve-
related mortality and morbidity [17].  Descriptive statistics were presented as mean ± standard deviation.  
Actuarial survival was calculated using the Kaplan-Meier method with 95% confidence limits.  Data was 
collated using Microsoft Access, and statistical analysis was performed using the SPSS statistical package 
(SPSS Inc, Chicago, Illinois). 
 
Results 
The mean follow-up of the patient cohort was 4.3 years (SD 2.6 years, range 0 - 10.4 years).  All but four 
patients survived (30 day/hospital mortality = 0.99%).  The early mortality was 0.6% for the 329pts<80 
yrs of age and 2.7% for the 73pts>80 yrs.  The four deaths were essentially valve unrelated 
(retroperitoneal haemorrhage from intra-aortic balloon insertion 1st day postoperative; aortic dissection 
from cardioplegic site 2nd day; ruptured spleen (patient fell out of bed, third day); and sudden death at 
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home (arrhythmia 29th day).  Of 398 patients, late mortality has occurred in 69 (17.3% - 39 days to 9.6 
years after operation).  Valve related deaths have occurred in two unoperated late endocarditis patients, 
dying of multisystem failure, beyond surgical retrieval.  Except for the debatable relationship that 
embolism has as a tissue valve related cause of death, all other reasons for death were readily explained on 
natural causes in this elderly patient cohort (e.g. cancer, cerebro- vascular accident, non-cardiac induced 
renal failure, respiratory infections).  The actuarial 8 year patient survival is 70.8% ± 7.1% (95% C.L.) 
[Fig 5] with thereafter, a less meaningful decline due to reduced patient numbers.  Eight of a possible 14 
patients who had their operation 11 years ago are still alive.  
Table 2 summarizes the morbidity events of thromboembolism (56 episodes in 40 patients), 
endocarditis (9), paravalvar leaks (6), structural degeneration (1) and reoperation (9 from all causes).  
Initially in this series, the first 83 patients were not temporarily warfarin anticoagulated during the 
initial postoperative weeks.  Three patients, all in new early postoperative atrial fibrillation, sustained 
peripheral (2) and cerebral (1) embolism.  Following this, all patients were anticoagulated for the first six 
to twelve weeks.  Patients having a late thromboembolic event were medicated with warfarin or aspirin - 
there being no universal policy.  Some patients who had a history of preoperative strokes eventually 
succumbed to late recurrent strokes while 23 elderly patients had a total of 29 episodes categorized as 
either Transient Ischaemic Attacks (TIA) or Reversible Ischaemic Neurological Deficits (RIND).  Patients 
were very closely questioned and a diagnosis made according to the well-established and recognized 
guidelines (17-18).  This final subjective conclusion was often considered difficult.  The actuarial 8 year 
freedom from thromboembolism of all types (82.1% ± 6.5%) and of thromboembolism causing permanent 
disability (90.0% ± 5.4%) are depicted in Fig 6 and 7. 
Other morbid events include 9 episodes of endocarditis (9 days to 5 years) over the 10 years of 
maximum follow-up.  There were seven staphylococcal and two streptococcal infections.  The event 
appearance comprised early endocarditis at nine days in one patient and late infection at five months to 
five years in the remaining eight patients.  No patient, 5 years after AVR, sustained an infection.  The 
actuarial freedom from the endocarditis was 97.1% ± 2.0% at 8 years [Fig 8].  In 5 of the 9 patients, the 
valve did not become dysfunctional, remaining completely competent on serial echocardiography.  Of 
these 5 patients, two died of septicaemia and multi-organ failure and three were medically cured of the 
acute endocarditis.  One of the latter three sustained a ventricular septal defect and another an expanding 
subvalvar abcess cavity as a result of the now sterile infection. Reoperations were performed, the VSD 
closed and the cavity patched.  Both valves remained competent on the last echoes some two years after 
reoperation. Three patients required valve explantation in the acute phase of the endocarditis. One of the 
three patients died of continuing septicaemia and multi-organ failure after re-operation.  
Paravalvar leaks have not been a problem of recent years.  However two patients did require 
reoperation.  One patient obviously had two loose a suture and, at reoperation at 10 days, valve repair 
cured the problem.  The other patient at 3 months returned with severe acute incompetence.  At 
reoperation a 4/0 polypropylene suture had broken.  A stronger suture along the disrupted segment was 
sufficient to repair the valve.  A successful long-term outcome following both valve repairs has been 
verified by late echocardiography.  Since these episodes, occurring early in this series, a stronger suture 
has been used ie 3/0 polypropylene (No 8936 on a small taper cut half-circle V5 needle, Ethicon, 
Somerville, NJ).  Four other patients without clinical murmurs of incompetence have presumed minor 
non-progressive paravalvar leaks detected echocardiographically. 
The actuarial 8 year freedom from reoperation due to all causes was 96.7% ± 2.3% [Fig. 9] and 
the freedom from valve explantation was 97.8% ± 2.1% [Fig. 10].  Reoperation [Table 2] has been 
required for 9 patients with the explanting of 5 stentless valves.  Explantation has been for endocarditis at 
1.5yrs, 2yrs and 3.5yrs after initial operation; for technical needle damage in a patient who had moderate 
incompetence on hospital discharge with subsequent progression until reoperation at 1.3yrs, revealing an 
unusual square-shaped hole in the belly of the leaflet, which looked in all other respects normal; for 
structural degeneration at 5 years, the leaflet tearing away near one of but not at a commissure.  There has 
been therefore one structural valve failure in the 402 implants requiring reoperation over the ten years. 
The graphical depiction of the actuarial freedom from structural failure is therefore unnecessary and not 
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presented.  An interesting observation has been made that this composite stentless valve, in the absence of 
endocarditis, is very easy to remove.  The host aortic sinus wall attachment to the small rim of 
glutaraldehyde preserved xenograft wall is very easily separated with forceps alone once in the correct 
plane and after the knots of the continuous suture are cut.  There has been no obvious macroscopic 
calcification detected in the xenograft wall of any of these explants (note, except for a diluted ether wash, 
this valve has no anti-calcium agent in the preservation protocol). 
Echocardiography (conventional transthoracic) revealed that most patients, in the late post-
operative phase, had a nil/trivial degree of non-progressive incompetence (Table 3). No living patient at 
last review during 2002-2003 had severe valve incompetence.   
Transvalvar gradients and effective orifice areas have been almost but not quite as good as the 
homograft valve [9] i.e. at 6 months post-implant stentless valve for a 21mm host annulus, the mean 
gradient is of the order of 9.8mmHg and orifice area 1.56cm2; for a 27mm host annulus, the mean gradient 
is 7.3mmHg and the orifice area 2.7cm2.  Left ventricular mass regression has been previously reported 
[22]; comparison of pre and post- operative regression was significant (P = 0.0001).  The mean of the 
mean and peak transvalvar gradients from the large number of echoes are summarized in Table 4.  A 
similar analysis of those 42 patients who had an associated LV myomectomy is presented in Table 5.  The 
gradients were similar to those patients who did not receive a myomectomy.  All 42 patients survived and 
clearly experienced a very smooth immediate post-operative course.  In fact it was a subjective clinical 
impression, over the years, that not only these patients, but virtually all stentless valve patients, had good 
post-op progress without low cardiac output states.  The MRI studies with annular extensibility may be an 
explanation for this observation.  Some years ago, more esoteric echocardiographic studies suggested 
interesting observations of the aortic root post-implant.  Analysis by 3/4 dimensional echo demonstrated 
dynamic changes in the size of the aortic root and valve annulus during the cardiac cycle.  In retrospect, 
these findings confirmed the more recent accurate and readily documented MRI studies  
MRI Studies demonstrated significant variation in the cross sectional area of the aortic annulus 
throughout the cardiac cycle at rest in all 10 patients so far examined.  The mean increase in cross 
sectional area of the aortic orifice was 37% of the smallest area in diastole.  This would appear possible if, 
at operation, the calcified native valve is excised, the annulus aggressively decalcified and the valve 
implanted supra-annularly.  The MR images demonstrated the ability of this valve annulus to ‘expand and 
relax’ significantly throughout the cardiac cycle.  Peak flow volumes corresponding to peak ejection 
during ventricular systole occurred just prior to maximal annular dilation (Fig 4).  
Comment 
The long term durability of this stentless xenograft beyond 10 years is still unknown.  This present review 
of the CryoLife-O’Brien valve to the beginning of the 11th year shows promise with only one reoperation 
for structural failure so far.  Because the use of this valve has been largely confined to elderly patients, 
future analyses of both patient survival and valve durability will be influenced by the competing risk of 
death due to natural causes.  The immediate results are very good with less than 1% early mortality in 402 
patients who, at this age with 63% requiring associated procedures, would be classed as a moderately high 
risk group. 
David et al [19-20] described a case controlled patient study with an actuarial survival at 8 years 
of 91% ± 4% with the Toronto SPV patient group and of 69 ± 8% for the Hancock stented porcine 
xenograft group (P = 0.0006).  The study was perhaps flawed by dissimilar groups and by the individual 
fact that the stentless valve group seemed to be inexplicably ‘immune’ to the usual expected natural 
causes of death in any elderly patient group.  Del Rizzo et al [21] analyzed survival with patients receiving 
either the Medtronic Freestyle stentless valve or the Hancock II porcine valve.  Of interest, was the 
significant advantage of the stentless valve in patients younger than 60 years; the probability of death was 
five-fold greater with the Hancock than Freestyle valves.  With advancing age the benefits of stentless 
valves were diminished. 
In this study of 402 patients, a significant morbid event occurred in 35 patients (8.7%); 22 
thromboembolism; 9 endocarditis; 4 reoperations – excluding those for acute endocarditis.  The interesting 
observation with endocarditis is made that the actual infection may occur more on the native host annulus, 
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where turbulence is maximum and speed of flow greatest, than primarily on the supra-annular xenograft.  
In support of this observation is that in the endocarditis patients all but four of the nine continued to have 
a competent valve and four of the nine were medically cured of the infection without replacement of the 
valve.  
The incidence of thromboembolic events may seem high.  The data collection has been assiduous 
and may, in comparison with other studies, tend to overestimate the overall incidence of 
thromboembolism, especially by including all “suggestive” TIA events.  During data collection in our 
institutions, the determination of a higher incidence of thromoembolic events may likely be over-
estimated as our many published clinical homograft analyses always had a patient thromboembolic 
incidence, unlike that of many similar publications by others.  It is considered that a stentless tissue valve 
is unlikely to be the primary site of thromboemboli especially in this elderly group of patients, prone to 
innate carotid and cerebro-vascular disease and to developing early and late postoperative arrhythmias.  
Forty-six percent of patients required CABG for coronary atherosclerosis.  Except in the presence of 
endocarditis, thrombus on any stentless tissue valve has not been seen by the surgical authors.  However, 
although the stentless valve itself may be exonerated as the likely focus of thrombus giving rise to an 
embolic episode, the possibility does exist, especially with supra-annular xenograft valve implantation, 
that the subvalvar area i.e. the actual denuded native valve annulus, may be a primary thrombotic site.  No 
early or late echocardiographic studies have suggested thrombus in these denuded areas.  In addition, an 
early higher incidence of thromboembolism has not been found.  Of the 40 patients who sustained 
thromboembolism, four episodes were early (less than one month after operation), and all of these were 
transient ischaemic episodes.  Because thromboembolism in this patient study has been more of a late 
phenomenon than an early event, then the denuded native valve annulus site is far less of an important 
cause of thromboembolism.  Of equal interest is the observation that of the 42 patients who had a 
myomectomy, only one (at 16 days postoperative) had a transient ischaemic episode.  Of this group, a 
further six had a late thromboembolic episode (4 months to 6.3 years). 
The details of serial echocardiography have previously been documented [10].  They have not 
changed over time and hence are not repeated in this presentation except to state that 94% of patients have 
either nil/trivial or mild degree of incompetence on echocardiography across time.  In addition, echo 
studies have shown no dilatation of the aortic root in this elderly patient cohort.  Therefore, no sino-
tubular diameter changes have been observed and no specific surgical sino-tubular fixation techniques 
have been necessary in retrospect.  Progression of incompetence has been rare and cannot be attributed to 
any root dimensional changes.  An interesting comparison of hemodynamics and LV mass regression 
between the CryoLife-O’Brien stentless and the supra-annular Carpentier-Edwards stented porcine valve 
has been reported from our institution by Thomson et al [22].  Briefly, at 6 months the mean gradients 
were lower (p = 0.001), the effective orifice greater (p = 0.05) and the Dimensionless Performance Index 
higher in the stentless versus the stented group.  There was important LV mass regression at 6 months 
after operation in both groups, but the reduction was greater in the stentless (p = 0.04).   
Evidence has certainly accumulated that stentless valves enhance LV hypertrophic regression 
faster and more completely than do stented valves. Jin et al. [23] compared the hemodynamic data of 
homografts, stentless (Toronto SPV™) and stented valves. Both types of stentless valves caused less 
resistance to LV ejection and produced greater early improvement in LV function and consequently more 
complete resolution of LV hypertrophy.  These important findings were verified by Del Rizzo et al. [26] 
with the Toronto SPV valve. 
The highly favorable echocardiographic features probably reinforce the opinion that good 
hemodynamics facilitate good recovery, low mortality and morbidity.  The subjective impressions that 
these elderly patients feel ‘so well’, much better than their stented valved colleagues, suggest also that 
exercise induced variations in cardiac output are more possible and better tolerated with a stentless valve.  
While a comparative study during exercise has not been completed, the new techniques of 3/4D echo and 
especially MRI studies are focusing our attention and that of Dagun et al [24] to the restoration towards 
normality of the aortic annulus during the dynamic phases of the cardiac cycle.  During isovolumic 
contraction both the annulus and sinotubular junction underwent rapid circumferential expansion.  The 
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MRI conclusions in all 10 patients examined so far were even more significant as the studies were carried 
out some years (mean 6yrs) after valve implantation.  These recent findings with the CryoLife-O’Brien 
supra-annular valve raise several questions.  Will the restoration of annular extensibility be an important 
reason for the improved durability of this particular valve implanted supra-annularly?  If so, how can it be 
proven?  The opposite view of course is – does stent mounting and annular fixation diminish durability?  
This was perhaps clearly answered years ago with our own experience and that of others with the stentless 
and stented homograft [25].  The latter valve had decreased durability.  In addition, the former earlier 
version of this composite porcine valve in our hands in the late 1960s demonstrated that the actuarial 50% 
freedom from structural degeneration of the formaldehyde composite valve (if stented) was only 2.5 yrs 
while that of the similar preserved but composite non-stented three non-coronary leaflet valve was 5 yrs.  
In summary, it may be difficult to prove that the presence of annular extensibility is important in 
improving durability.  No further assistance in this debate can come from the homograft which, in its late 
phase, becomes fibrotic and even calcified in its intra-annular implantation site.  However the autograft 
may well show annular extensibility but other variables such as its ability to grow coupled with the 
presence of viable leaflet tissue capable of cellular replenishment, would confuse the issue and the debate. 
The possible advantages of stentlessness are many.  This stentless valve has some of the early 
attributes of the aortic homograft valve.  In the small aortic root, its performance is excellent and where an 
additional LV myomectomy is indicated, all such elderly patients have had a very smooth postoperative 
course.  In essence no stent should imply no obstruction.   
The effective orifice within a given host aortic root is much greater compared to other stented 
mechanical or stented biological protheses.  This applies particularly to the CryoLife-O’Brien valve 
where, for example, a 27mm valve is inserted supra-annularly into a 25mm host annulus.  Although the 
xenograft leaflets are a little stiff, they still produce a low mean transvalvar gradient almost but not quite 
as good as that of the homograft valve.  
 Although most elderly patients are suitable candidates for this valve, there are nevertheless, three 
contraindications. Firstly, excessive aortic root calcification may preclude suturing in the supra-annular 
and peri-commissural aortic wall tissue.  This probably applies as well to other models of stentless valves 
using subcoronary implantation.  Such calcification is not common, but if present, an alternative stented 
bioprosthesis should wisely be chosen.  In this series, no stentless valve implantation has had to be  
abandoned in the middle of implantation because of aortic wall calcification.  This decision has always 
been made on inspection of the aortic root, prior to selection of the particular valve.  Secondly, the large 
aortic annulus (>30mm) is a contraindication for this valve, the largest size of which is a 29mm CryoLife-
O’Brien valve.  Thirdly, for the subcoronary supra-annular implant of this type of stentless xenograft, 
gross asymmetry of the aortic root (bicuspid valve with a transverse orifice), although rare in the elderly, 
may produce a less desirable result than that obtainable with a stented xenograft valve.  Fortunately, most 
elderly patients have a symmetrical trileaflet configuration to their calcific aortic valve stenosis. 
Stentless valves are technically more difficult to implant compared to stented bio-prostheses or 
mechanical valves.  In addition, implantation techniques are more difficult to learn and more difficult to 
teach.  Not every surgical center is interested in adopting a program of stentless valve usage, which 
requires the interested surgeon to focus more on aortic root symmetry, orientation of a trileaflet valve, 
measurement of annular and sinotubular diameters. Ultimately patient understanding, cooperation and 
preference are essential for patient factors, pathological valve disease factors and surgeon factors dictate 
valve choice and the final short and long-term outcome.  Why should a surgeon choose a stentless valve 
over a stented valve such as the commonly used stented pericardial valves?  Surgical techniques are 
simpler with the stented bioprostheses and probably the immediate outcomes with either valve used by the 
same surgical team are no different.  The authors consider it is a good forward-looking research concept to 
gather data from patients having a variety of valves in order that 15-20 years comparative analyses can be 
forthcoming.  The authors have a large patient cohort with stented pericardial valves. 
Patient Age Selection.  From the very onset of this patient study with a new bioprosthesis in 1992, 
the decision was made to restrict this stentless valve to elderly patients.  This was because the durability 
record of glutaraldehyde preserved stented aortic porcine valves in younger patients was so unsatisfactory, 
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requiring many re-operations in the 1980s, that their use was virtually discontinued.  The stented 
xenograft was relegated to elderly patients where the subsequent record proved and has remained 
acceptable. So, a careful approach in the early 1990s with this stentless valve was adopted in using it only 
for elderly patients. 
 The time has come to wisely use the stentless valve in the less than 60yr age group.  While the 
homograft gives an excellent record in this age group, the supply of such valves is becoming in many 
countries more and more of an insurmountable problem.  In such situations a stentless porcine valve may 
fill the hiatus.  This latter scenario of use in younger patients is indicated even more in countries where 
rheumatic valve disease predominates and in countries where anticoagulants are best avoided.  If this 
stentless valve begins to be used in younger, non-rheumatic patients, the more frequent findings of an 
asymmetrical aortic root may constitute a contra-indication to its use.  Aortic root tailoring techniques 
may not reliably correct such asymmetry long-term.  Therefore, for the younger patient, wise decisions in 
valve choice become more crucial for optimal long-term results. 
Conclusion 
The CryoLife-O’Brien stentless composite porcine aortic valve has proven itself to be a reliable device in 
the elderly patient cohort in this series in these two institutions by this surgical team.  The low immediate 
operation mortality and good long term survival is most acceptable especially considering that the patient 
cohort is elderly and destined to die of natural causes.  The incidence of morbid events is considered low 
for this patient group.  Of the total patient cohort of 402, the solitary single valve structural failure 
requiring reoperation over the maximum ten years with a 100% patient follow up may be the crucial 
objective observation.  This valve has rewarded its recipients with a good device. 
 From the research and scientific arena, the MRI findings of restoring the post-implant aortic 
annular extensibility, in relation to the dynamics of the cardiac cycle, may be one of the most important 
findings of a valve that is truly stentless and mounted supra-annularly.  
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Table 1.  Valve size, host patient valve annulus diameter and the number of patients 
 
 
Size of Porcine Valve 
Selected (mms) 
 
Likely Host Annulus Diameter 
(mms) 
 
 
Number of Patients 
19 <19  Nil 
21 <20  17 
23 21  53 
25 23  125 
27 25  114 
29 27  93 
 TOTAL  402 
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Table 2. Late Morbidity Events Of 398 Patients Dec 1992 – Dec 2002 
THROMBOEMBOLISM (56 episodes in 40 patients)  
 Cerebro-vascular    
  - CVA permanent • 23 episodes in 18 patients 
  - TIA and RIND  • 29 episodes in 23 patients 
 Retinal • 1 patient 
 Peripheral arterial embolism  • 3 patients – two early post-op in atrial 
fibrillation (coiled embolus removed 
at embolectomy), one mesenteric 
artery embolus 
ENDOCARDITIS  (n = 9) • 4 patients medically cured - no valve 
dysfunction.  (See reoperations below 
for two of these patients) 
 • 2 patients died - fulminating 
septicaemia and multi-organ failure 
 • 3 patients explanted at reoperation 
PARAVALVAR LEAK    (n = 6) • 2 patients reoperated and leak 
successfully repaired without valve 
replacement 
 
 
• 4 patients mild - 
echocardiographically detected only 
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STRUCTURAL DEGENERATION    (n = 1) 
 
• 1 explanted - (Leaflet tear) see below 
in reoperations 
REOPERATIONS    (n = 9) 
 
• 2 Paravalvar leaks - successful repairs 
[10th day, 3 months (broken 4/0 
polypropylene suture)] 
 • 5 Acute Endocarditis - 3 explants at  
1.5yrs, 2 yrs, 3.5yrs  
                                            - 2 valves left 
      in situ:    both cured endocarditis:  
* closure of expanding subvalvar 
sterile ‘abscess cavity’ (7 mths), 
* VSD closure (2yrs) 
 • 1 Technical  -  explant at 1.3yr for 
needle perforation damage 
 • 1 Structural degeneration - leaflet tear 
(5yrs) 
 
CVA – Cerebro-Vascular Accident 
TIA – Transient Ischaemic Attacks 
RIND – Reversible Ischaemic Neurological Deficit 
VSD – Ventricular Septal Defect 
 
Table 3.  Aortic Valve Incompetence on Echocardiography 
  
 
Degree 
 
Grading Nomenclature 
 
Number of Patients 
0 Nil-Trivial  297 
1 Mild  45 
2 Moderate  9 
3 Moderate +  3 
4 Severe  0 
Unknown   11 
Total patients echoed   365 
Patients with no late echo   33 
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Table 4.  The Transthoracic Echocardiographic Transvalvar Gradients in the Late Post Operative 
Studies in Patients in Table 3. 
Size of Valve 
(mms) 
Patient Annulus 
(mms) 
Mean of all MEAN 
gradients (mmsHg) 
Mean of all PEAK 
gradients (mmsHg) 
19 <19 0.0 0.0 
21 <20 12.7 23.4 
23 21 10.0 19.13 
25 23 8.8 16.7 
27 25 8.0 14.7 
29 27 6.8 12.7 
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Table 5. The Late Echocardiographic Results of the 42 Patients who have had an Associated LV 
Myomectomy  
 
Size of Valve 
(mms) 
No of Patients 
Echoes Performed 
Mean of all MEAN 
Gradients (mmsHg) 
Mean of all PEAK 
Gradients (mmsHg) 
19 0 0.0 0.0 
21 16 9.1 18.3 
23 34 10.7 20.4 
25 46 8.6 15.9 
27 26 7.6 13.8 
29 6 8.5 16.0 
 
   LV – Left Ventricular 
 
 
 
 
 
 
 
 
 
 
 
LEGEND FOR FIGURES 
 
Fig 1 Supra-annular implantation maximizes the effective orifice compared to the reduced 
orifice with the intra-annular implantation. With complete valve excision and 
thorough annular decalcification, the exposed annulus would appear capable of 
having its ability ‘to dilate’ restored. 
 
Fig 2 The aortic valve annulus is seen as an area of low signal intensity beneath the valve 
on Steady-state free precession imaging. 
 
Fig 3 (a) Phase Contrast images are acquired directly through the annulus, orthogonal to the 
left ventricular outflow tract; (b) resultant Magnitude and (c) Phase images of the 
aortic valve annulus. 
 
Fig 4 The mean cross-sectional area of the aortic valve annulus (4a) and the mean flow 
volumes (4b) were calculated at 30 intervals throughout the cardiac cycle and plotted 
against each point of the cardiac cycle.  
 
Fig 5 Actuarial patient survival expresses the number of patients at risk over 10 years. The 
actual number of deaths over 10 years and the actuarial freedom at 8 years is 
expressed with CL = 95% Confidence Limits. 
 
Fig 6 Actuarial freedom from thromboembolism of all grades of severity (See Table 2) 
Depiction as in Fig 5. 
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Fig 7 Actuarial freedom from thromboembolism causing a permanent disability (see 
Table 2). Depiction as in Fig 5. 
 
Fig 8 Actuarial freedom from endocarditis. The nine episodes all occurred within the 
first 5 years after aortic valve replacement (see Table 2). Depiction as in Fig 5. 
 
Fig. 9 Actuarial freedom from reoperation due to all causes (see Table 2). Depiction 
as in Fig 5. 
 
Fig 10 Actuarial freedom from valve explantation at 8 years was 97.82% ± 2.08%.  
Depiction as in Fig 5. 
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Fig 5 
 
 
 
No of patients at risk 
   321  207  112   48   6 
At 8 years 
70.8% ± 7.1%
73 deaths from all causes
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Fig 6 
 
 
 
 
 
No of patients at risk 
 306 186 102 41  3 
At 8 years 
82.1% ± 6.5% 
56 episodes in 40 patients
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*includes 1 death from mesenteric artery embolism 
 
Fig 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No of patients at risk 
 307 188 103  42   3 
At 8 years 
90.0% ± 5.4% 
24 episodes in 19 patients*
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Fig 8 
No of patients at risk 
 317 206 111  48  6 
At 8 years 
97.1% ± 2.0% 
9 infections
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Fig 9 
 
 
 
No of patients at risk 
   319 204 109 47 6 
At 8 years 
96.7% ± 2.3% 
9 operations
 
 
27
0.0 2.0 4.0 6.0 8.0 10.0
Years post AVR
0.90
0.92
0.94
0.96
0.98
1.00
Fr
ee
do
m
Freedom From Re-replacement
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 10 
 
 
 
 
 
 
 
 
Fig 4b 
No of patients at risk 
 319  204 109 47  6
At 8 years 
97.8% ± 2.1% 
5 re-replacements
